New platform methodology of drug screen using in vivo imaging technique of neuronal activity

The drug screening platform using fiber photometry for real-time neuronal activity assessment addresses inefficiencies in current technologies by enabling rapid identification of drug candidates through real-time neuronal activity monitoring, reducing variability and time, and allowing multiple drug tests in a single animal model.

KR103043031B1Active Publication Date: 2026-11-06KOREA ADVANCED INST OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020240066625
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-05-22
Publication Date
2026-11-06
Estimated Expiration
2041-07-01

AI Technical Summary

Technical Problem

Current drug screening technologies are inefficient and time-consuming, primarily relying on phenotype observations in experimental animals, making it difficult to determine drug efficacy for diseases involving specific neurons, and require significant time and cost due to inter-individual variability and the inability to repeatedly test drugs in a single animal model.

Method used

A drug screening platform using a fiber photometry device inserted into target neurons in the brain to observe neuronal activity in real-time, enabling rapid assessment of drug efficacy by selecting and targeting specific neurons, administering drugs, and observing changes in neuronal activity.

Benefits of technology

Enables rapid identification of drug candidates by tracking neuronal stimulation or inhibition in real-time, allowing multiple drug tests in the same animal model, reducing variability and confirming drug effects within a short period.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024055488820-PAT00004_ABST
    Figure 112024055488820-PAT00004_ABST
Patent Text Reader

Abstract

The present invention relates to a novel drug screening technique using in vivo imaging of neuronal activity. Specifically, the present invention relates to a platform for screening drugs for treating diseases involving neurons, utilizing an animal model in which a fiber photometry device is inserted into target neurons in the brain involved in a specific behavior or disease, thereby enabling real-time observation of changes in the activity of target neurons in vivo after drug administration. Furthermore, the present invention relates to a method for screening drugs for treating diseases involving neurons, comprising the steps of: (i) selecting and targeting brain neurons involved in a specific behavior or disease; (ii) administering a drug to an animal model in which a fiber photometry device is inserted into the target neurons in the brain; (iii) observing changes in the activity of target neurons in real-time in vivo; and (iv) screening drugs based on the changes in activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a novel drug screening technique using in vivo imaging of neuronal activity. Specifically, the present invention relates to a platform for screening drugs for treating diseases involving neurons, utilizing an animal model in which a fiber photometry device is inserted into target neurons in the brain involved in a specific behavior or disease, thereby enabling real-time observation of changes in the activity of target neurons in vivo after drug administration. Furthermore, the present invention relates to a method for screening drugs for treating diseases involving neurons, comprising the steps of: (i) selecting and targeting brain neurons involved in a specific behavior or disease; (ii) administering a drug to an animal model in which a fiber photometry device is inserted into the target neurons in the brain; (iii) observing changes in the activity of target neurons in real-time in vivo; and (iv) screening drugs based on the changes in activity. Background Technology

[0002] Current drug screening technologies are primarily based on the observation of phenotypes in experimental animals. For example, in the case of appetite suppressants, drugs are discovered through the effects of phenotypes such as food intake, fat cell size, and body weight. However, since food intake and body weight are influenced by other factors such as visceral pain and disease, it is difficult to determine whether the effects are solely due to the drug. Furthermore, because various drugs cannot be repeatedly compared within a single animal model, screening drugs during the drug discovery phase requires significant time and cost.

[0003] Cui et al. (Cui et al., 2013; Gunaydin et al., Cell, 2014) reported a technique called fiber photometry. However, to the knowledge of the inventors, there is no known method to screen for drugs targeting behaviors or diseases involving specific neurons by measuring neuronal activity in real-time in living animal models.

[0004] In particular, in the development of drugs targeting diseases involving nerve cells, there is a need to develop new drug screening platform technologies that can effectively assess the efficacy of the drugs within a short period of time. Prior art literature

[0005] Cui, G., et al. Concurrent activation of striatal direct and indirect pathways during action initiation. Nature 494(7436): 238-242 (2013).Gunaydin, LA, et al. Natural neural projection dynamics underlying social behavior. Cell 157.7 1535-1551 (2014). The problem to be solved

[0006] Accordingly, the technical objective of the present invention is to provide a new drug screening platform technology capable of effectively determining the efficacy of a drug within a short period of time in the development of drugs targeting diseases involving specific nerve cells. means of solving the problem

[0007] The inventors conducted research to solve the above-mentioned problem and, as a result, discovered that by inserting a fiber photometry device into target neurons in a mouse brain and observing changes in the activity of target neurons in real-time in vivo after drug administration, the effect of the drug can be effectively determined in a short period of time, thereby completing the present invention.

[0008] Accordingly, the present invention provides a platform for drug screening for the treatment of diseases involving neurons, utilizing an animal model in which a fiber photometry device is inserted into target neurons in the brain involved in specific behaviors or diseases, thereby enabling real-time observation of changes in the activity of target neurons in vivo after drug administration.

[0009] The present invention also provides a method for screening drugs for treating diseases involving neurons, comprising: (i) selecting and targeting brain neurons involved in a specific behavior or disease; (ii) administering a drug to an animal model in which a fiber photometry device is inserted into the target neurons of the brain; (iii) observing changes in the activity of the target neurons in real time in vivo; and (iv) screening drugs based on the changes in activity. Effects of the invention

[0010] The animal model and drug screening method for screening drugs for treating diseases involving nerve cells according to the present invention can track in real time whether target nerve cells in the brain of a living animal are stimulated by a specific drug to become activated or inhibited, thereby enabling the identification of much more promising drug candidates than experiments conducted at the cellular level.

[0011] In addition, the effect of the drug can be confirmed within a short period of time by observing rapid changes in the activity of target neurons, and since the effects of various drugs can be compared multiple times in the same animal, drugs can be screened with high efficiency.

[0012] In addition, it is possible to screen and identify drugs that affect target brain neurons from the drug discovery stage, regardless of whether the drug crosses the blood-brain barrier (BBB), and since various drugs can be repeatedly tested on the same animal, it has the advantage of low variability caused by inter-individual diversity. Brief explanation of the drawing

[0013] FIG. 1 schematically illustrates an animal model for drug screening and a drug screening method according to the present invention. FIG. 1A is a photograph of a mouse with a fiber photometry device inserted, and FIG. 1B is a schematic diagram showing the principle of the fiber photometry technique. Figure 2 schematically illustrates a mouse animal model and experimental process targeting AgRP neurons. Figure 3 shows the location and function of AgRP neurons. Figure 3A shows the location of AgRP neurons in the brain, and the neurons emitting green fluorescence are AgRP neurons. Figure 3B is a schematic diagram showing the function of AgRP neurons. Figure 3C shows the fiber photometry results of AgRP neurons before and after ghrelin administration. Figure 4 shows the results of fiber photometry for targeting and reliability confirmation in a mouse animal model using ghrelin (fasting hormone), a known positive control for AgRP neurons. Figure 5 shows the results of fiber photometry using phentermine, a known appetite suppressant, as a positive control that inhibits AgRP neurons. Figure 6 shows heatmap data of some compounds from the results of a large-scale cocktail primary screening using a clinical compound library. Figure 7 shows heatmap data of some compounds from the results of large-scale cocktail primary screening using a clinical compound library. Figure 8 shows heatmap data of some compounds from the results of large-scale cocktail primary screening using a clinical compound library. Figure 9 shows representative fiber photometry results of the activator group that stimulates the activity of AgRP neurons among the cocktail groups. Figure 10 shows representative fiber photometry results of the inhibitor group that inhibits the activity of AgRP neurons among the cocktail groups. Figure 11 shows the average ΔF / F (%) value of the fiber photometry results for cocktail groups of various compounds, including the CCL-D1-13-3 cocktail group and the CCL-D1-13-12 cocktail group. The CCL-D1-13-5 group confirmed the ghrelin effect even in a cocktail of ghrelin and 7 drugs. Figure 12a shows the raw trace of the fiber photometry results of the CCL-D1-13-3 group. Figure 12b shows the raw trace of the fiber photometry results of tretinoin, a compound of the CCL-D1-13-3 group. Figure 13 shows the results of fiber photometry for targeting and reliability confirmation in a mouse animal model using desipramine, a positive control used as an antidepressant / tranquilizer, against CRF neurons in the paraventricular nucleus (PVN). Figure 14 shows the fiber photometry results of other antidepressants / tranquilizers desipramine, venlafaxine, and fluoxetine. Specific details for implementing the invention

[0014] The inventors discovered that by inserting a fiber photometry device into target neurons in a mouse brain and observing changes in the activity of target neurons in real-time in vivo after drug administration, the effect of the drug can be effectively determined in a short period of time.

[0015] Specifically, the inventors obtained the clinical compound library (consisting of 2,900 clinical Phase I-III compounds and approved drugs) from the Korean Chemical Bank (chembank.org) and evaluated the real-time effects of each compound on the activity of AgRP neuronal colonies in mice using fiber photometry. To evaluate as many types of compounds as possible within a short period, eight compounds were mixed into a cocktail for primary screening. Prior to the cocktail screening, the inventors confirmed that the unique effects of each drug on neuronal activity were preserved even when administered as a cocktail, using the commercially known appetite suppressant phentermine and the appetite stimulant ghrelin. Subsequently, based on the results of the cocktail screening, individual screening candidates were selected, and each compound within the candidate group was evaluated individually. As a result, compounds that inhibit or promote the activity of AgRP neuronal colonies were discovered. In addition, CRF neurons were screened using the same method, and it was observed that the activity of CRF neuron clusters was inhibited when commercially approved antidepressants (Desipramine, Fluoxetine, Venlafaxine, etc.) were injected. It was confirmed that this effect was largely preserved even when injected as a cocktail.

[0016] Based on the above findings, in one aspect, the present invention provides a platform for screening drugs for treating diseases involving neurons, using an animal model in which a fiber photometry device is inserted into target neurons in the brain involved in a specific behavior or disease, and changes in the activity of the target neurons can be observed in real-time in vivo after drug administration.

[0017] In another aspect, the present invention provides a method for screening drugs for treating diseases involving neurons, comprising: (i) selecting and targeting brain target neurons involved in a specific behavior or disease; (ii) administering a drug to an animal model in which a fiber photometry device is inserted into the target neurons of the brain; (iii) observing changes in the activity of the target neurons in real time in vivo; and (iv) screening drugs based on the changes in activity.

[0018] In the present invention, fiber photometry was used as an in vivo imaging technique. Fiber photometry is a type of calcium imaging technique that allows the experimenter to target only the desired type of nerve cells within a desired brain region and observe the activity of the corresponding nerve cell population in real time (Fig. 1).

[0019] In neurons, calcium flows into the cell during an action potential; GCaMP is a protein whose structure is modified to emit fluorescence when bound to calcium, and it is used as a fluorescent indicator of neuronal activity. By injecting a viral vector encoded with both GCaMP and loxP sequences into the brain of a Cre-mouse capable of targeting the desired type of neuronal, the GCaMP protein can be expressed in specific desired neurons. Additionally, to deliver light to excite the GCaMP protein while simultaneously receiving real-time signals of changes in the intensity of the emitted light reflected through a color-selecting mirror, a cannula embedded with an optical fiber is implanted along with the viral vector during injection.

[0020] In the drug screening platform and drug screening method of the present invention, the animal may be any animal capable of inserting a fiber photometry device, and specifically may be a mammal. In one embodiment, the animal may not be a human. In another embodiment, the animal may be a mouse. Specifically, the mouse may be a Cre-mouse, and more specifically, the Cre-mouse may be a transgenic mouse that specifically expresses the GCaMP protein in target neurons.

[0021] In the drug screening platform and drug screening method of the present invention, the target neuron may be a neuron that governs appetite. Specifically, the neuron that governs appetite is an AgRP (agouti-related peptide) neuron in the arcuate nucleus (ARC) region of the hypothalamus. In one embodiment, in the drug screening platform and drug screening method of the present invention, if the activity of the AgRP neuron is observed to decrease after drug administration, the administered drug may be determined to be an appetite suppressant drug. In another embodiment, if the activity of the AgRP neuron is observed to increase after drug administration, the administered drug may be determined to be an appetite stimulant drug.

[0022] In the drug screening platform and drug screening method of the present invention, the target neuron may be a neuron that governs stress. Specifically, the neuron that governs stress may be a corticotropin-releasing factor (CRF) neuron in the paraventricular nucleus (PVN) region of the hypothalamus. In one embodiment, in the drug screening platform and drug screening method of the present invention, if the activity of the CRF neuron is observed to decrease after drug administration, the administered drug may be determined to be a stress inhibitor drug. In another embodiment, if the activity of the CRF neuron is observed to increase after drug administration, the administered drug may be determined to be a stress promoter drug.

[0023] Although the following embodiments describe a mouse animal model targeting AgRP neurons and a drug screening method using the same, and a mouse animal model targeting CRF neurons and a drug screening method using the same, a person skilled in the art will understand that the drug screening platform and drug screening method of the present invention can be applied to all types of neurons. Drug screening techniques targeting neurons related to specific behaviors or diseases correspond to the platform technology of the present invention.

[0024] In the drug screening platform of the present invention, changes in the activity of target neurons can be observed for 20 to 40 minutes. Alternatively, in the drug screening method of the present invention, (iii) the step of observing changes in the activity of target neurons in real time in vivo can be performed for 20 to 40 minutes. The observation time for changes in neuronal activity may vary depending on the type of neuronal and the type of drug administered, but does not exceed 40 minutes. This allows the effect of the drug to be confirmed within a short period of time. Specifically, changes in neuronal activity can be observed for 20 minutes, 30 minutes, or 40 minutes. More specifically, changes in neuronal activity can be observed for 20 minutes.

[0025] The drug screening platform and drug screening method of the present invention can simultaneously screen eight or more drugs in a single animal model. As confirmed in the examples described below, at least eight drugs can be simultaneously screened in a single animal model. Specifically, examples of the number of drugs that can be simultaneously screened in a single animal model are eight, ten, fifteen, twenty, or more, and there is no upper limit on the number of drugs.

[0026] In addition, the drug screening platform and drug screening method of the present invention can repeatedly test multiple drugs five or more times in a single animal model. Using animal cells in vitro Drug screening technology typically allows for only a single test of a drug in a single animal cell. However, the drug screening platform and drug screening method of the present invention make it possible to repeatedly test various drugs multiple times in a single animal model. Specifically, multiple drugs can be repeatedly tested five or more times, ten or more times, twenty or more times, or more times in a single animal model.

[0027] In the drug screening platform and drug screening method of the present invention, it will be understood that "diseases involving neurons" may include any disease that can be treated, alleviated, or relieved by stimulating or inhibiting neurons. In one embodiment, where the target neuron is a neuron that governs appetite, and more specifically, where the neuron that governs appetite is an AgRP neuron, the "disease involving neurons" may be obesity or underweight. In another embodiment, where the target neuron is a neuron that governs stress, and more specifically, where the neuron that governs stress is a CRF neuron, the "disease involving neurons" includes, but is not limited to, depression, anxiety disorder, post-traumatic stress disorder (PTSD), panic disorder, manic-depressive disorder, bipolar disorder, etc.

[0028] The drug screening platform and drug screening method of the present invention can track in real time whether target neurons in the brain of a living animal are stimulated or inhibited by a specific drug, thereby enabling the identification of much more promising drug candidates than experiments conducted at the cellular level.

[0029] In addition, the effect of the drug can be confirmed within a short period of time by observing rapid changes in the activity of target neurons, and since the effects of various drugs can be compared multiple times in the same animal, drugs can be screened with high efficiency.

[0030] In addition, it is possible to screen and identify drugs that affect target brain neurons from the drug discovery stage, regardless of whether the drug crosses the blood-brain barrier (BBB), and since various drugs can be repeatedly tested on the same animal, it has the advantage of low variability caused by inter-individual diversity.

[0031] The structure and effects of the present invention will be explained in more detail below through examples. These examples are solely for the purpose of illustrating the present invention, and the scope of the present invention is not limited by these examples.

[0033] Examples

[0034] Example 1: Construction of a drug screening platform targeting AgRP neurons

[0035] Materials and Methods

[0036] mouse

[0037] All AgRP-ires-Cre mice (B6(Cg)- used in the experiment Agrp tm1(cre)Lowl Jackson Laboratory, stock no. 012899) was reared individually in a 12-hour light / dark cycle (light cycle from 7:00 to 19:00), and feed and water were provided on a free basis.

[0039] Compound treatment

[0040] All compounds used in the experiment were obtained from the clinical compound library of the Korean Chemical Bank (chembank.org) (consisting of 2,900 clinical phase I-III compounds and approved drugs) in a state dissolved in DMSO (Dimethyl Sulfoxide) at a concentration of about 5 mM, and injected into the peritoneal cavity of mice using saline as a secondary solvent.

[0041] In the cocktail screening of 8 compounds, 1.25 µl of the compound (a total of 10 µl since 8 compounds were mixed) was injected per mouse into 10 ml / kg of physiological saline based on the mouse's weight. In the individual screening, 10 µl of the compound was injected into 10 ml / kg of physiological saline based on the mouse's weight.

[0043] Stereotaxic surgery

[0044] AAV1-CAG-Flex-GCaMP6 virus (500 nl, 1.9×10⁶ 13 Genomic copies per ml (University of Pennsylvania Vector Core) were stereotactically injected into the unilateral arcuate nucleus (ARC) of AgRP-ires-Cre mice (bregma: AP: -1.75 mm, ML: ±0.3 mm, DV: -5.9 mm; from the skull surface). Figure 2 schematically illustrates the mouse animal model and experimental procedure targeting AgRP neurons.

[0045] The Drummond Nanoject III microinjector was used. During the surgery, a cannula with a single optical fiber (6 mm, core diameter = 400 μm, numerical aperture of 0.48; Doric lenses, MFC_400 / 430-0.48_5mm_ZF2.5_FLT) was implanted to the upper part of the ARC (-5.6 mm DV point) and sealed with dental cement (C&B Metabond, S380). Immediately after surgery, 5 mg / kg of ketoprofen was administered into the peritoneal cavity of the mice, followed by a recovery period of 3–4 weeks in individual cages.

[0047] GCaMP / Fiber photometry

[0048] To excite the fluorescence of the GCaMP6 protein, a 400-Hz sinusoidal blue light-emitting diode (473 nm) (30 μW) (LED: M470F1; LED driver: LEDD1B, Thorlabs) was bandpass filtered (passband: 472±15 nm, Semrock, FF02-472 / 30-25) and a dichroic mirror was used to reflect light of 473 nm wavelength while transmitting the fluorescence of the excited GCaMP6 protein. Additionally, bandpass filtered light (passband: 535±25 nm, Semrock, FF01-535 / 50-25) was detected by a femtowatt silicon photodetector (Newport, 2151) and converted into a digital signal and recorded by a real-time processor (RP2.1, TDT). The neural signals obtained in real time and the behavioral patterns of experimental animals recorded in real time were synchronized using StreamPix 6 (Norpix) video recording software.

[0050] In Vivo Recording

[0051] AgRP-ires-Cre mice that had recovered from surgery were initially selected based on the inhibition of neuronal activity induced by the inhaled anesthetic isoflurane (assessed using real-time fiber photometry signals) and secondarily selected based on the trends in fiber photometry signals following the intraperitoneal injection of phentermine (an appetite suppressant, which was repeatedly observed to inhibit AgRP neuronal activity in the described experimental environment). Meanwhile, all mice underwent a 20-minute acclimatization period in the experimental chamber prior to selection.

[0052] GCaMP fluorescence signals were first recorded at a baseline of 20 minutes, followed by an additional 20–30 minutes from the time of intraperitoneal injection of the compound into the mice to observe the drug's effects (Fig. 2). Each time point was manually analyzed by annotating sequence files recorded at 25 frames per second on StreamPix 6 using Caltech Behavior Annotator code written in MATLAB. (All mice underwent a 20-minute acclimatization period in the experimental chamber prior to the experiment.)

[0053] In the analysis of drug effects, the averaged GCaMP fluorescence signal (F) represented the raw information value of the GCaMP signal, and the average ΔF / F (%) value was the average of the F values ​​after drug treatment (F duration ) and the average of the F-values ​​of the signals recorded from -300 seconds to -5 seconds (F baseline Based on ), (F duration -F baseline ) / F baseline It was calculated as ×100.

[0055] Post-hoc verification

[0056] The brains of the mice used for screening were frozen-sectioned by injecting PFA (paraformaldehyde) via cardiac perfusion, and the expression of GCaMP6 protein in the ROI was verified by imaging GFP signals using a slide scanner or confocal microscopy. The location of the ARC during the analysis was<Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates> I referred to books.

[0058] result

[0059] AgRP (agouti-related peptide) neurons are located in the arcuate nucleus (ARC) region of the hypothalamus, and the green-fluorescent neurons in Fig. 3A are AgRP neurons. AgRP neurons are a very important group of neurons that enables the mammalian brain to sense appetite (see Fig. 3B). Fig. 3C shows the fiber photometry results of AgRP neurons before and after the administration of ghrelin (a hormone secreted during fasting), which acts as a signal of hunger. It can be seen that the activity of the AgRP neuron population rises sharply in response to ghrelin and is inhibited again upon food intake. Therefore, if a specific drug inhibits the activity of AgRP neurons, it can be considered that there is a possibility of reducing appetite even without food intake.

[0060] AgRP-ires-Cre mice, having undergone AAV1-CAG-Flex-GCaMP6 virus injection and cannula insertion, were validated before use for screening. Fiber photometry recordings were performed using negative and positive controls to verify whether the fiber optic cable was properly targeted at AgRP neurons in the ARC and whether the GCaMP6 protein was properly expressed within the AgRP neurons. Physiological saline was used as the negative control, which does not significantly affect the activity of the AgRP neuron population, while ghrelin, which has already been confirmed in other studies to increase AgRP neuron activity and stimulate appetite, was used as the positive control. The fiber photometry results for the negative and positive controls are shown in Figure 4. As shown in Figure 4, physiological saline used as the negative control did not significantly affect the activity of AgRP neurons (Figures 4A and 4B), whereas ghrelin used as the positive control was found to stimulate the activity of AgRP neurons (Figures 4C and 4D). The average ΔF / F (%) value of the above fiber photometry results is shown in Fig. 4E.

[0061] In this way, using ghrelin, it was confirmed that the optical fiber is properly targeted to the AgRP neurons of the ARC and that the GCaMP6 protein is properly expressed within the AgRP neurons.

[0062] Meanwhile, since substances with great potential for development as drugs in modern times are likely to be substances that inhibit AgRP neurons (i.e., substances that suppress appetite) rather than substances that activate AgRP neurons (i.e., substances that stimulate appetite), we tested previously known appetite suppressants on AgRP neurons to find a positive control group that inhibits AgRP neurons. As a result, as shown in Fig. 5A, it was confirmed that phentermine, a known appetite suppressant, inhibits the activity of AgRP neurons. Furthermore, as shown in the heatmap data in Fig. 5B, this effect was observed in all four mice starting from the time of phentermine injection. The average ΔF / F (%) value of the fiber photometry results is shown in Fig. 5C.

[0063] As described above, after securing a positive control group, a large-scale cocktail primary screening was conducted using a clinical compound library, and the results are shown in Figures 6 to 8. Representative fiber photometry results of the activator group, which stimulates AgRP neuronal activity among the cocktail groups, are shown in Figure 9. Additionally, representative fiber photometry results of the inhibitor group, which inhibits AgRP neuronal activity among the cocktail groups, are shown in Figure 10. As a result of the large-scale cocktail primary screening, the activator group and the inhibitor group shown in Table 1 below were obtained first.

[0065] [Table 1]

[0066]

[0068] Among these, the highest inhibitory effect was observed in the CCL-D1-13-3 group. The average ΔF / F (%) values ​​of the fiber photometry results for various compound cocktail groups, including the CCL-D1-13-3 and CCL-D1-13-12 groups listed in Table 1 above, are shown in Figure 11. As shown in Figure 11, according to the graph in the red dotted box on the left showing the effect of the CCL-D1-13-3 group, it can be seen that the inhibitory effect continued from 0 minutes to 15 minutes after injection. In addition, as shown in the raw trace of the CCL-D1-13-3 group in Figure 12a, the CCL-D1-13-3 group strongly inhibited the activity of AgRP neurons.

[0069] Therefore, individual secondary screening was performed on the hit CCL-D1-13-3 group, which showed the highest inhibitory effect, and as a result, it was confirmed that one compound "Tretinoin" in the CCL-D1-13-3 group inhibited the activity of AgRP neurons (Fig. 12b). Tretinoin is a compound having the following structural formula and is known for its use in inhibiting obesity; this validates that the drug screening platform technology of the present invention can actually screen for effective drugs.

[0070]

[0072] Example 2: Construction of a drug screening platform targeting CRF neurons

[0073] Materials and Methods

[0074] mouse

[0075] All CRF-ires-Cre mice (B6(Cg)- used in the experiment Crh tm1(cre)Zjh Jackson Laboratory, stock no. 012704) was reared individually in a 12-hour light / dark cycle (light cycle from 7:00 to 19:00), and feed and water were provided on a free basis.

[0077] Compound treatment

[0078] FDA-approved antidepressants Desipramine, Fluoxetine, and Venlafaxine were prepared by dissolving them in DMSO (Dimethyl Sulfoxide) at a concentration of approximately 5 mM, and injected into the peritoneal cavity of mice using saline as a secondary solvent. 10 µl of the compound was injected via 10 ml / kg of saline based on the mouse's weight.

[0080] Stereotaxic surgery

[0081] AAV1-CAG-Flex-GCaMP6 virus (120 nl, 1.9×10⁶ 13 Genomic copies per ml (University of Pennsylvania Vector Core) were stereotactically injected into the unilateral paraventricular nucleus (PVN) of CRF-ires-Cre mice (bregma ML: 0.2 mm, AP: -0.75 mm, DV: -4.7 mm; from the skull surface).

[0082] The Drummond Nanoject III microinjector was used. During the surgery, a cannula with a single optical fiber (5 mm, core diameter = 400 μm, numerical aperture of 0.48; Doric lenses, MFC_400 / 430-0.48_5mm_ZF2.5_FLT) was implanted to the upper part of the PVN (at the -4.3 mm DV point) and sealed with dental cement (C&B Metabond, S380). Immediately after surgery, 5 mg / kg of ketoprofen was administered into the peritoneal cavity of the mice, followed by a recovery period of 3–4 weeks in individual cages.

[0084] GCaMP / Fiber photometry

[0085] To excite the fluorescence of the GCaMP6 protein, a 400-Hz sinusoidal blue light-emitting diode (473 nm) (30 μW) (LED: M470F1; LED driver: LEDD1B, Thorlabs) was bandpass filtered (passband: 472±15 nm, Semrock, FF02-472 / 30-25) and a dichroic mirror was used to reflect light of 473 nm wavelength while transmitting the fluorescence of the excited GCaMP6 protein. Additionally, bandpass filtered light (passband: 535±25 nm, Semrock, FF01-535 / 50-25) was detected by a femtowatt silicon photodetector (Newport, 2151) and converted into a digital signal and recorded by a real-time processor (RP2.1, TDT). The neural signals obtained in real time and the behavioral patterns of experimental animals recorded in real time were synchronized using StreamPix 6 (Norpix) video recording software.

[0087] In Vivo Recording

[0088] CRF-ires-Cre mice that had recovered from surgery were initially selected based on the inhibition of neuronal activity induced by the inhaled anesthetic isoflurane (assessed using real-time fiber photometry signals), and secondarily selected based on the trend of fiber photometry signals during the tail suspension test (TST; stress induction in rodents). Meanwhile, all mice underwent a 20-minute acclimatization period in the experimental chamber prior to selection.

[0089] GCaMP fluorescence signals were first recorded at a baseline of 20 minutes, followed by an additional 20–30 minutes from the time of intraperitoneal injection of the compound to observe the drug's effects. Sequence files recorded at 25 frames per second using StreamPix 6 were manually analyzed by annotating them with Caltech Behavior Annotator code written in MATLAB. (All mice underwent a 20-minute acclimatization period in the experimental chamber prior to the experiment.)

[0090] In the analysis of drug effects, the averaged GCaMP fluorescence signal (F) represented the raw information value of the GCaMP signal, and the average ΔF / F (%) value was the average of the F values ​​after drug treatment (F duration ) and the average of the F-values ​​of the signals recorded from -300 seconds to -5 seconds (F baseline Based on ), (F duration -F baseline ) / F baseline It was calculated as ×100.

[0092] Post-hoc verification

[0093] The brains of the mice used for screening were frozen-sectioned by injecting PFA (paraformaldehyde) via cardiac perfusion, and the ROI expression of GCaMP6 protein was verified by imaging GFP signals using a slide scanner or confocal microscopy. The location of the PVN during analysis was<Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates> I referred to books.

[0095] result

[0096] Corticotropin-releasing factor (CRF) neurons are located in the paraventricular nucleus (PVN) region of the hypothalamus and are neurons that regulate stress. Results from the tail suspension test (TST) on experimental mice showed that when stress is induced by tail stimulation, the activity of CRF neuron populations rises sharply and is inhibited again when the stimulation is stopped. Therefore, if a specific drug inhibits the activity of CRF neurons, it can be considered to have the potential to reduce stress.

[0097] CRF-ires-Cre mice that had undergone AAV1-CAG-Flex-GCaMP6 virus injection and cannula insertion were validated before being used for screening. Fiber photometry recordings were performed using negative and positive controls to confirm whether the optical fibers were properly targeted at CRF neurons in the PVN and whether the GCaMP6 protein was properly expressed within the CRF neurons. DMSO, a vehicle, was used as the negative control, which did not significantly affect the activity of the CRF neuron population, while desipramine, a known antidepressant, was used as the positive control. The fiber photometry results for the negative and positive controls are shown in Fig. 13. As shown in Fig. 13, DMSO, used as the negative control, did not significantly affect the activity of CRF neurons (Figs. 13B and 13D), whereas desipramine, used as the positive control, was found to inhibit the activity of CRF neurons (Figs. 13A and 13C). The average ΔF / F (%) value of the above fiber photometry results is shown in Fig. 13E.

[0098] In this way, using desipramine, it was confirmed that the optical fiber is properly targeted to the CRF neurons of the PVN and that the GCaMP6 protein is properly expressed within the CRF neurons.

[0099] Additionally, the known antidepressants venlafaxine and fluoxetine were tested on CRF neurons, and the results are shown in Fig. 14. For comparison of the data, the results of the desipramine treatment group are also shown. As shown in Fig. 14, it was observed that venlafaxine and fluoxetine, like desipramine, inhibited the activity of CRF neurons. The average ΔF / F (%) values ​​of the fiber photometry results are shown in Fig. 14F. As shown in Fig. 14F, high inhibitory effects were observed in the order of venlafaxine, fluoxetine, and desipramine, and in particular, desipramine most significantly inhibited the activity of the CRF neuron population. These results validate that the drug screening platform technology of the present invention can actually screen for effective drugs.

Claims

Claim 1 A drug screening platform for treating diseases involving neurons, utilizing a mouse model in which a fiber photometry device is inserted into target neurons in the brain involved in specific behaviors or diseases, thereby enabling real-time observation of changes in the activity of target neurons in vivo after drug administration, wherein the target neurons are AgRP neurons that govern appetite or CRF neurons that govern stress. Claim 2 A drug screening platform according to claim 1, characterized in that the target neuron is an AgRP neuron that controls appetite, and if a decrease in the activity of the AgRP neuron is observed, the administered drug is determined to be an appetite suppressant drug, and if an increase in activity is observed, the administered drug is determined to be an appetite stimulant drug. Claim 3 A drug screening platform according to claim 1, wherein the target neuron is a CRF neuron that governs stress, and if a decrease in the activity of the CRF neuron is observed, the administered drug is determined to be a stress inhibitor drug, and if an increase in activity is observed, the administered drug is determined to be a stress promoter drug. Claim 4 A drug screening platform according to claim 1, characterized in that the mouse is a Cre-mouse. Claim 5 A drug screening platform according to claim 4, characterized in that the Cre-mouse is a transgenic mouse that specifically expresses the GCaMP protein in target neurons. Claim 6 A drug screening platform according to paragraph 2, characterized in that the disease involving nerve cells is obesity or underweight. Claim 7 A drug screening platform according to claim 3, characterized in that the disease involving neurons is depression, anxiety disorder, post-traumatic stress disorder (PTSD), panic disorder, manic-depressive disorder, or bipolar disorder. Claim 8 A drug screening platform according to claim 1, characterized by being able to simultaneously screen eight or more drugs in a single mouse model. Claim 9 A drug screening platform according to claim 1, characterized by being able to repeatedly test multiple drugs five or more times in a single mouse model. Claim 10 A drug screening platform according to claim 1, characterized by observing changes in the activity of target neurons for 20 to 40 minutes. Claim 11 A drug screening method for treating diseases involving nerve cells using a platform according to any one of claims 1 to 10.